The study will evaluate safety, tolerability and PK profile of BPL-003 in healthy subjects
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of subjects with treatment emergent AEs (TEAES)
Timeframe: From screening through to the follow up visit, up to 65 days